FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

Recruiting now · Phase 2

Conditions studied: Colorectal Liver Metastasis (CRLM)

In brief

Try FOLFOX-HAIC combining bevacizumab or cetuximab for initially unresectable colorectal liver metastasis patients to increase the conversion to resection rate to improve long-term survival outcomes

Key facts

Study ID
NCT06988852
Run by
Tongji Hospital
People needed
300
Starts
2023-05-01
Expected to finish
2030-12-31
Last updated by the study team
2025-05-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.